MerTK inhibitors represent a specialized category of chemical compounds designed to specifically target and impede the activity of the MerTK receptor tyrosine kinase. MerTK, an abbreviation for Mer Tyrosine Kinase, is a prominent member of the TAM (Tyro3, Axl, and Mer) family of receptor kinases, which exert pivotal control over numerous cellular processes. Predominantly expressed on the surfaces of phagocytic cells, such as macrophages and dendritic cells, MerTK activation plays a central role in recognizing and engulfing apoptotic cells and cellular debris, a fundamental aspect of the body's immune response and tissue equilibrium. However, when MerTK becomes dysregulated or experiences overexpression, it has been linked to various diseases, including cancer, autoimmune disorders, and chronic inflammation.
Consequently, MerTK inhibitors have been meticulously engineered to selectively disrupt MerTK's signaling pathways. These inhibitors primarily function by binding to the catalytic site of MerTK, effectively obstructing the receptor's ability to phosphorylate downstream signaling molecules. Consequently, they interrupt its cellular functions, exerting influence over vital processes such as phagocytosis, cytokine production, and interactions between immune cells. The ramifications of MerTK inhibition extend to diseases characterized by irregular cell clearance, immune evasion, or tissue remodeling. Researchers are continually refining MerTK inhibitors, exploring their capacity to address health challenges associated with MerTK-related cellular pathways.
VEJA TAMBÉM
Items 1 to 10 of 13 total
Mostrar:
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inibe as tirosina-quinases, em particular a BCR-ABL e a c-KIT, bloqueando as vias de sinalização celular nas células cancerígenas. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Tem como alvo as cinases RAF e VEGFR, impedindo a proliferação celular e a angiogénese no cancro. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Inibe o recetor do fator de crescimento epidérmico (EGFR), impedindo o crescimento e a divisão celular no cancro do pulmão. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Bloqueia o recetor de androgénio, impedindo a sua ativação nas células cancerígenas da próstata. | ||||||
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | $392.00 $1244.00 | 1 | |
O BMS-777607 é um inibidor da tirosina quinase multiobjectivo. O seu mecanismo envolve a ligação aos locais de ligação ATP das cinases MET, AXL, Ron e Tyro3, entre as quais a MerTK é inibida. A sua natureza multi-alvo sugere que pode ser bloqueada uma gama mais vasta de vias oncogénicas. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Inibe o mTOR, reduzindo o crescimento celular e a angiogénese em vários tipos de cancro. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Tem como alvo o EGFR, impedindo o crescimento celular no cancro do pulmão de células não pequenas. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Inibe JAK1 e JAK2, modulando a sinalização de citocinas em neoplasias mieloproliferativas. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Bloqueia múltiplas tirosina-quinases, incluindo BCR-ABL, inibindo o crescimento na leucemia mieloide crónica. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Tem como alvo tanto o EGFR como o HER2, interrompendo as vias de sinalização nas células do cancro da mama. |